comparemela.com
  1. Home
  2. Live Updates
  3. Obinutuzumab Vs - Breaking News

Latest Breaking News On - Obinutuzumab vs - Page 1 : comparemela.com

Long-Term Data for Up-Front Combinations Reaffirm Treatment Options in CLL

Kathleen A. Dorritie, MD, discusses long-term data from trials in chronic lymphocytic leukemia presented at the 2023 ASH Annual Meeting.

United statesKathleena dorritieHillman cancer centerUniversity of pittsburghUniversity of pittsburgh medical centerDivision of oncologyPittsburgh medical centerObinutuzumab vsTreatment naive chronic lymphocytic leukemiaYear follow up

Acalabrutinib With or Without Obinutuzumab Provides Sustained PFS Benefit in Previously Untreated CLL

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.

United statesAcalabrutinib calquenceJeffp sharmanUs oncology networkWillamette valley cancer instituteObinutuzumab vsTreatment naive chronic lymphocytic leukemiaYear follow upPatients with treatment naive chronic lymphocytic leukemiaElevate tn trialThe us oncology network

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.